Bifidobacterium bifidum does not show cell toxicity on leukemic cells of AML patients but induced cell death on K562 cell line
Abstract
Background: Leukemia is a kind of blood cancer diseases which are generally known as neoplasm. There are two types of blood cancer called acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). This type of leukemia targets plasma cells and prevents the production of antibodies in the body and makes the immune system vulnerable to infections.
Methods: Blood samples from 10 people with AML and 10 normal individuals were collected who were defined as the case and control groups, respectively. PBMCs were isolated by Ficoll hypaque and cultured in order to the MTT assay. Then, the cell wall of Bifidobacterium bifidum bacterium was treated in five concentrations on these cells and the MTT test was performed at 24, 48 and 72hrs. Also, K562 leukemia cell was cultured then after; the MTT test was performed in the same protocol. The expression of BAX, Bcl2, β-actin genes were assessed by real-time PCR after 48 and 72hrs of treatment.
Results: The results of MTT test could not show any significant differences in extracted PBMCs from individuals as compared to control group. But, K562 cell line in treatment with the cell wall of Bifidobacterium bifidum showed a significant cell toxicity effect at 48 and 72hrs versus non-treated K562 cells. BAX gene expression was significantly increased versus β-actin gene control only on K562 cell line, but not on AML derived leukemic cells.
Conclusion: According to the obtained results, Bifidobacterium bifidum, as a probiotic bacterial species, can impact the growth and/or proliferation of cancer cells; however, it could depend on the type of cancer cells.
2. Naclerio F, Larumbe-Zabala E, Ashrafi N, et al. Effects of protein–carbohydrate supplem-entation on immunity and resistance training outcomes: a double-blind, randomized, controlled clinical trial. Eur J Appl Physiol 2017; 117:267-77.
3. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clinic Proceedings Elsevier, 2016, p. 81-3.
4. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3:380.
5. Abla O, Coco FL and Sanz MA. Acute Promyelocytic Leukemia: A Clinical Guide. Springer, 2018.
6. Bultz BD and Carlson LE. Emotional distress: the sixth vital sign in cancer care. J Clin Oncol 2005; 23:6440-1.
7. Mrózek K, Marcucci G, Paschka P, Whitman SP and Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 2007; 109:431-48.
8. Silverman L, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 2008; 26(15):7000-.
9. Chui PL, Abdullah KL, Wong LP, et al. Complementary and alternative medicine use and symptom burden in women undergoing chemotherapy for breast cancer in Malaysia. Cancer Nurs 2018; 41:189-99.
10. Oun R, Moussa YE and Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton trans 2018; 47:6645-53.
11. Lehouritis P, Stanton M, McCarthy FO, et al. Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria. Journal Control Release 2016; 222:9-17.
12. Wang Y, Wu Y, Wang Y, et al. Antioxidant properties of probiotic bacteria. Nutrients 2017; 9: 521.
13. Floch M. Recommendations for probiotic use in humans—a 2014 update. Pharmaceuticals 2014; 7:999-1007.
14. Kailasapathy K. Microencapsulation of probiotic bacteria: technology and potential applications. CIIM 2002; 3:39-48.
15. Fotiadis CI, Stoidis CN, Spyropoulos BG, et al. Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol 2008; 14:6453.
16. Ambalam P, Raman M, Purama RK and Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Cl Ga 2016; 30:119-31.
17. Lee JW, Shin JG, Kim EH, et al. Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. J Vet Sci 2004; 5:41-8.
18. Liong MT. Roles of probiotics and prebiotics in colon cancer prevention: postulated mechanisms and in-vivo evidence. Int J Mol Sci 2008; 9:854-63.
19. Kageyama T, Tomoda T, Nakano Y. The effect of Bifidobacterium administration in patients with leukemia. Bifidobacteria and Microflora 1984; 3:29-33.
20. Kim N, Kunisawa J, Kweon MN, et al. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4+ CD45RBhigh T cell-mediated inflammatory bowel disease by inhibition of disordered T cell activation. J Clin Immunol 2007; 123:30-9.
21. Marin M, Lee J, Murtha J, et al. Differential cytokine production in clonal macrophage and T-cell lines cultured with bifidobacteria. J Dairy Sci 1997; 80:2713-20.
22. Zarei L, Esmaeili GGH, Grajehdagi A, et al. The effects of Bifidobacterium bifidum (BBCWF) on proliferation of K562 cell line. Journal of Fasa University of Medical Sciences 2017; 7:21-7.
| Files | ||
| Issue | Vol 9 No 1-2 (2020) | |
| Section | Original Articles | |
| Keywords | ||
| AML Bifidobacterium Leukemic blasts Probiotics. | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
